ACE and COVID-19: Additionally, in a retrospective multicenter study conducted in China, with 1128 hypertensive patients diagnosed with COVID-19 (188 received ACE inhibitors or ARB and 940 without receiving ACEI/ARB), the mortality rate was higher in the population that did not receive ARB/ACEI drugs (9.8% vs. 3.7%) [239].